Risks of Serious Infection or Lymphoma With Anti–Tumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease: A Systematic Review
- 1 September 2014
- journal article
- review article
- Published by Elsevier BV in Clinical Gastroenterology and Hepatology
- Vol. 12 (9), 1443-1451
- https://doi.org/10.1016/j.cgh.2014.01.021
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in ChildrenGastroenterology, 2012
- Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative ColitisClinical Gastroenterology and Hepatology, 2011
- Pediatric modification of the Montreal classification for inflammatory bowel diseaseInflammatory Bowel Diseases, 2011
- Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trendsInflammatory Bowel Diseases, 2011
- Severe Pediatric Ulcerative Colitis: A Prospective Multicenter Study of Outcomes and Predictors of ResponseGastroenterology, 2010
- Strategies to improve quality of life in adolescents with inflammatory bowel diseaseInflammatory Bowel Diseases, 2009
- Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in ChildrenGastroenterology, 2007
- Specificities of inflammatory bowel disease in childhoodBest Practice & Research Clinical Gastroenterology, 2004
- Longitudinal Growth in Children and Adolescents with Inflammatory Bowel DiseaseJournal of Pediatric Gastroenterology and Nutrition, 1994
- Decreased Height Velocity in Children and Adolescents Before the Diagnosis of Crohn's DiseaseGastroenterology, 1988